U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second ...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On ...
(RTTNews) - Rapport Therapeutics (RAPP) announced that the Phase 2a clinical trial of RAP-219 in patients with drug-resistant focal onset seizures met its primary endpoint, demonstrating a ...
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results